Announcements Trials
Browse Landscape

Phase

Phase 2 64Phase 1 55Phase 1/2 54Phase 3 44Phase 2/3 5Phase 4 4

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 5NIH 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 3Gastrointestinal 1

Conditions

Melanoma 3Uveal Melanoma 2Neoplasm Metastasis 1Colorectal Neoplasms 1Advanced or Metastatic Solid Malignancies 1

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9anlotinib 7Trastuzumab 7Injections 7Rituximab 6atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5venetoclax 4Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Albumin-Bound Paclitaxel 4sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Ipilimumab × Clear all
NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

NCT06581406 2026-04-02

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Replimune, Inc.

Phase 2/3 Recruiting
280 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

IDEAYA Biosciences

Phase 2/3 Active not recruiting
420 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT04887870 2025-10-10

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Mirati Therapeutics Inc.

Phase 2/3 Completed
52 enrolled

Advanced or Metastatic Solid Malignancies

NCT05141721 2025-05-16

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Seattle Project Corporation

Phase 2/3 Active not recruiting
700 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡